A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults.

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04530565

Study #:
STUDY00148026

Start Date:
May 25, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04530565

View Complete Trial Details & Eligibility at ClinicalTrials.gov